NHS services provided at new health hub for north Oxford
"Attracting staff is hard at the best of times," he said. "Students are taught in a multi-disciplinary way - and that's what they would expect to see in a workplace."Our teams, sitting together, can actually start to talk to each in a way they just didn't before because they were located in different parts of the city."The trust plans to create three hubs in the city, one at the existing East Oxford Health Centre on Manzil Way and another for the south in the Blackbird Leys area.Mr Gibson said Murray House was "a much, much better facility [and] easier for people to get to, with much better public transport links".
Katie Lennon, who runs the reception team at Murray House, said a patient "might be able to see a podiatrist at 10 o'clock and a district nurse at half past 10".She said Oxford Health will use Murray House as "a learning tool" so future hubs will be "equipped with as much information as they can".Staff started moving in toward the end of April, with the first patients arriving by 5 May.An official opening ceremony is expected to be held later this year.
You can follow BBC Oxfordshire on Facebook, X, or Instagram.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
18 minutes ago
- The Independent
‘Doctors thought I had a stroke after Botox injection'
Nicola Fairley is one of 38 cases of botulism so far linked to unlicensed anti-wrinkle injections in recent outbreak of disease many doctors have never treated. Fairley was left unable to swallow and doctors thought she had suffered a stroke after contracting the life-threatening illness from a potentially illegal product. The botox was administered by her usual beautician after she won a Facebook competition. Botulism symptoms include slurred speech, breathing problems and can be deadly, it's so rare many doctors never see it in their entire careers.
ITV News
an hour ago
- ITV News
UK-India trade deal sparks fears over access to cheap medicines for millions
A newly signed trade agreement between India and the UK has triggered concerns that millions of poor Indians may lose access to affordable life-saving medicines. Civil society groups and health experts say the UK-India Free Trade Agreement (FTA), finalised between two countries, tilts the balance in favour of multinational pharmaceutical corporations and threatens to erode long-standing protections that have allowed India to produce low-cost generic drugs. 'This is not just about trade. It's about whether a person living on ₹200 (£2) a day can afford cancer treatment or survive tuberculosis,' said Jyotsna Singh, co-convenor of the Working Group on Access to Medicines and Treatments. At the heart of the controversy are the agreement's intellectual property (IP) provisions, which activists say may restrict the Indian government's ability to issue compulsory licences—legal tools that allow domestic companies to manufacture patented drugs at reduced prices during public health emergencies. India used this provision in 2012 to dramatically cut the price of sorafenib, a cancer drug sold by Bayer under the brand Nexavar. Generic versions slashed the monthly cost by nearly 97%, from ₹2.8 lakh (£2,600) to around ₹8,800 (£80), making it affordable to thousands. 'By discouraging compulsory licensing and promoting voluntary licences, the deal hands over control of access to medicines to the market,' said Prof Biswajit Dhar, a trade expert and former professor at New Delhi's Jawaharlal Nehru University. 'Voluntary licences often come with strings attached and don't bring the same price reductions.' Weakening India's Patent Safeguards Under the FTA, companies will no longer need to report annually how their patents are being 'worked'—or used—in India. Instead, disclosures can be made every three years, and some information can be kept confidential. Activists say this undermines transparency and makes it harder to prove that a drug isn't available to the public, a key step in applying for a compulsory licence. There are also concerns the deal could open the door to 'evergreening'—a tactic in which companies make minor changes to existing drugs and claim new patents. Indian law currently limits this practice under Section 3(d) of the Patents Act, but experts warn the FTA's emphasis on 'harmonisation' of IP standards with Western countries could override such protections. 'This is effectively a backdoor entry for TRIPS-plus provisions,' said K.M. Gopakumar, co-convenor of the Working Group. 'It would push India to grant unnecessary patents, prolonging monopolies and delaying cheaper alternatives.' The Indian pharmaceutical industry supplies more than 60% of global vaccines and a significant share of affordable generics to low- and middle-income countries. Critics say the FTA may limit this capacity and ultimately have consequences well beyond India's borders. Government response The Indian government has promoted the FTA as a landmark deal that will boost exports and attract UK investment in manufacturing, services, and digital trade. Officials insist that India has preserved its ability to protect public health. But rights groups remain unconvinced. 'You cannot negotiate away access to life-saving drugs in the name of free trade,' said Gargeya Telakapalli, a public health campaigner based in Hyderabad. 'The poorest Indians—those with cancer, HIV, diabetes, or TB—are being quietly sacrificed.' Broader implications The deal follows a similar agreement India signed last year with the European Free Trade Association (EFTA), which also faced criticism for diluting IP safeguards. Observers say the trend may reflect a shift in India's trade policy as it seeks closer ties with Western economies. But for many in India's healthcare and legal communities, the question remains: how much access to medicine is the country willing to give up for a better trade balance? From Westminster to Washington DC - our political experts are across all the latest key talking points. Listen to the latest episode below...
Metro
an hour ago
- Metro
Health warning over counterfeit vodka made with medical-grade alcohol
Health officials in Scotland have warned fans of Glen's vodka to keep an eye out for fake half bottles containing medical disinfectant. Scammers have hijacked the popular brand to sell counterfeit products containing the chemical isopropyl, which is typically used in hospital settings or in hand sanitiser. Food Standards Scotland (FSS) say the fake booze will smell and taste 'very different' to the Glen's product people recognise. Even small amounts of isopropyl can result in abdominal pain, vomiting, dizziness and headaches, they warned. Severe cases can leave drinkers in a coma or even dead. Genuine bottles of Glen's have a laser-etched code between the rear label and the base of the bottle which the fake bottles will not. More Trending Anyone concerned they might have drunk the counterfeit vodka, and who is experiencing symptoms, is urged to contact NHS 24 on 111 immediately. Glen's, one of the cheaper brands of vodka on the market, is a popular target for scammers. FSS has previously sent investigators to seize dozens of bottles of fake spirit using the same label from a shop in Coatbridge, Lanarkshire. And in September last year, the UK-wide Food Standards Agency sent out a warning about another fraud involving isopropyl alcohol in Glen's bottles. Get in touch with our news team by emailing us at webnews@ For more stories like this, check our news page. MORE: The one drink you should never order from a restaurant wine list MORE: How a generation-bending TikTok campaign saved a local boozer MORE: Forget about Prosecco — drink this £6.97 sparkling wine from Asda instead
